.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AG01_Nevirapine.Nevirapine .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AG01_Nevirapine.Nevirapine| name: | Nevirapine |
| ATC code: | J05AG01 | route: | oral |
| n-compartments | 1 |
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of human immunodeficiency virus (HIV)-1 infection. It is typically used in combination with other antiretroviral agents. Nevirapine is approved for use in adults and children and is available in oral tablet and suspension formulations.
Pharmacokinetic parameters in healthy adult volunteers; oral administration of 200 mg nevirapine twice daily.
Elsherbiny, D, et al., & Simonsson, US (2009). Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. European journal of clinical pharmacology 65(1) 71–80. DOI:10.1007/s00228-008-0481-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/18751690
Moltó, J, et al., & Clotet, B (2008). Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. The Journal of antimicrobial chemotherapy 62(4) 784–792. DOI:10.1093/jac/dkn268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18593723
Ibarra, M, et al., & Fagiolino, P (2014). Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose. Journal of pharmacokinetics and pharmacodynamics 41(4) 363–373. DOI:10.1007/s10928-014-9371-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25064169